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Hemolytic uremic syndrome (HUS) is a rare thrombotic com-
plication characterized by a triad of microangiopathic he-
molytic anemia, thrombocytopenia, and acute renal failure. 
HUS may be caused by several different conditions, including 
infection, malignancy, and chemotherapeutic agents, such 
as mitomycin, cisplatin, and most recently, gemcitabine. The 
outcome of gemcitabine-induced HUS is poor, and the dis-
ease has a high mortality rate. This study reports a case of 
gemcitabine-induced HUS in a patient with pancreatic cancer 
in Korea. (Gut	Liver	2014;8:109-112)
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INTRODUCTION
Gemcitabine-induced hemolytic uremic syndrome (HUS) is 
rare but can often be fatal. Early detection of HUS is critical so 
that contributing chemotherapeutic agents, such as gemcitabine, 
can be discontinued. In clinical trials, HUS is characterized by 
renal failure, microangiopathic hemolytic anemia (MAHA), and 
thrombocytopenia.1 In addition, the onset of new and uncon-
trolled hypertension can be diagnostic for HUS.2 
While a few cases of gemcitabine-induced HUS have been 
reported globally, but only a single Korean case of HUS in a 
lung cancer patient is known.3 With the increase in gemcitabine 
use in pancreatobiliary cancer, early detection of gemcitabine-
induced HUS is essential. Herein, we describe the first case of 
HUS in a pancreatic cancer patient, associated with gemcitabine 
use in a Korean hospital.
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CASE REPORT
In June 2011, a 56-year-old male visited a local hospital 
complaining of dyspepsia and back pain. Contrast-enhanced 
computed tomography (CT) revealed a 4.4 cm mass at the head 
of his pancreas (Fig. 1). He was referred to our hospital, where 
we found the mass had invaded the main portal vein, common 
hepatic artery, and stomach. An endoscopic biopsy revealed 
moderately differentiated adenocarcinoma. The patient was di-
agnosed with locally advanced, unresectable pancreatic cancer 
(cT4N1M0). Laboratory tests showed serum hemoglobin level 
of 14.9 g/dL, platelet count of 166,000/µL, blood urea nitrogen 
of 21.3 mg/dL, and serum creatinine level of 1.28 mg/dL. The 
carcinoembryonic antigen level was 2.34 ng/mL (normal range, 
0 to 5 ng/mL) and carbohydrate antigen 19-9 was 798 U/mL 
(normal range, 0 to 37 U/mL).
Fig. 1. Contrast-enhanced computed tomography revealed a 4.4-cm 
mass at the head of the pancreas, as indicated by the arrow.
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Concurrent chemoradiotherapy (CCRT) with original gem-
citabine weekly (1,000 mg/m2 per week, day 1, 8, 15, 22, and 
29) and 25 radiation therapy (total radiation dose, 4,500 cGy) 
was performed from June 30 to August 3, 2011. One month 
after CCRT, a repeat abdominal CT showed that the pancreatic 
mass had decreased from 4.4 to 3.0 cm but remained unresect-
able. The tumor response was considered a partial response to 
treatment. On October 21, 2011, gemcitabine therapy was ad-
ministered weekly (1,000 mg/m2 per week, day 1, 8, and 15) for 
3 out of 4 weeks. A cumulative dose of gemcitabine from June 
30, 2011 was 26,250 mg.
In February 2012 during week 2 of cycle 5, the patient was 
admitted for generalized edema and general weakness. He 
developed acute renal failure and had an elevated serum cre-
atinine level of 2.08 mg/dL (normal range, 0.5 to 1.40 mg/dL). 
On physical examination, the patient had dyspnea on exertion, 
lower extremity pitting edema, and a blood pressure of 200/140 
mm Hg. The patient’s hemoglobin level had decreased to 7.7 
g/dL (normal range, 13.0 to 17.0 g/dL) and a platelet count of 
87,000/µL (normal range, 150,000 to 400,000/µL). The reticu-
locyte count was 11.69% (normal range, 0.5% to 2.31%), with 
a corrected reticulocyte count of 6.6% and an elevated lactate 
dehydrogenase (LDH) level of 459 IU/L (normal range, 110 to 
247 IU/L). A peripheral blood smear showed macrocytic hy-
pochromic anemia with mild anisopoikilocytosis composed of 
schistocytes and acanthocytes (Fig. 2). There was no evidence of 
proteinuria or hematuria, but the patient was positive for urine 
hemoglobin. The patient’s total bilirubin, obtained from an in-
direct Coombs test, was normal and the patient’s haptoglobin 
level was <10 mg/dL.
The laboratory tests confirmed MAHA, thrombocytopenia, 
and acute renal failure–leading to a diagnosis of gemcitabine-
induced HUS. The patient started plasmapheresis due to oli-
guria and bilateral pleural effusion. After 19 plasmapheresis 
treatments, the patient’s creatinine level decreased to 2.02 mg/
dL and he was able to maintain self-urine output. The patient 
declined further chemotherapy due to his poor general condi-
tion after HUS treatment. He was transferred to a nursing home 
for hospice care and has continued with outpatient palliative 
therapy. 
DISCUSSION
HUS is characterized by renal failure, thrombocytopenia and 
MAHA characterized by a trio of classic symptoms–elevated 
LDH, low haptoglobin, and schistocytes on the peripheral blood 
smear. Five typical HUS cases were first described by Gasser 
et al. in a pediatric patient with hemorrhagic diarrhea and en-
terocolitis caused by verotoxin-producing Escherichia coli.4 In 
1979, a gastric cancer patient developed chemotherapy-related 
HUS associated with mitomycin C (MMC) and 5-fluorouracil.5 
The causes of atypical HUS include infectious diseases, malig-
nancy, antineoplastic agents such as MMC, antiplatelet agents, 
pregnancy, hemolytic anemia, elevated liver enzymes, and low 
platelet syndrome (HELLP syndrome), malignant hypertension, 
systemic lupus erythematosus, and antiphospholipid syndrome.
The incidence of gemcitabine-induced HUS is low (0.015% 
to 0.31%), but the mortality rate is as high as 50% in these pa-
tients. There have been previous reported cases in patients with 
nonsmall cell lung cancer, ovarian cancer, and metastatic breast 
cancer.6-8 A review of the literature revealed only 15 patients of 
gemcitabine-induced HUS in pancreatic cancer. These 15 cases 
are summarized in Table 1.1,2,9-15 Our case is noteworthy because 
of the first reported case in Korea. The mechanism of gemcitabi-
ne-induced HUS is unclear with hypotheses including micro-
vascular endothelial damage or immunocomplex mediation.9 
An increase of von Willebrand factor levels in HUS suggests a 
potential role in HUS, but further investigation is needed.5 In the 
literature, the median duration of gemcibatine therapy was 5.8 
months, with the majority of patients developing HUS within 1 
to 2 months of the last gemcitabine infusion.1 The median time 
between initiation of chemotherapy and onset of gemcitabine-
induced HUS was 7.4 months.16 Gemcitabine-induced HUS 
developed after an estimated median cumulative dose of 20,000 
mg/m2 with a broad range from 2,450 to 48,000 mg/m2 with no 
clear dose-response relationship.11 Our patient began develop-
ing symptoms of peripheral edema and hypertensive emergency 
after 7 months of therapy and a cumulative dose of 26,250 mg.
In patients treated with gemcitabine, HUS must be considered 
when uncontrolled hypertension or worsening preexisting hy-
pertension develops, and it is important to monitor blood pres-
sure to detect any early indication of gemcitabine-induced HUS. 
Although there is currently no consensus as to the best treat-
ment for gemcitabine-induced HUS, immediate discontinuation 
of gemcitabine is accepted as the initial step.17 Other treatment 
modalities include corticosteroids, transfusion of fresh frozen 
plasma, plasmapheresis, or hemodialysis. However, plasmapher-
Fig. 2. The peripheral blood smear showed macrocytic hypochromic 
anemia with schistocytes, as indicated by the arrows. 
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esis reportedly had no direct therapeutic effect, which was at-
tributed to discontinuing gemcitabine administration.18
To confirm a diagnosis of HUS, a renal biopsy can be per-
formed to show microvascular damage of arterioles and small 
arteries occluded by eosinophilic hyaline thrombi containing 
fibrin and platelet aggregates.1 Generally, the histopathology of 
renal tissue in patients with HUS shows characteristic throm-
botic microangiopathy consisting of thrombi in blood vessels, 
glomerular mesangiolysis, and widening of the subendothelial 
space with detachment of endothelial cells from the glomerular 
basement membrane.4 A renal biopsy was scheduled for the pa-
tient in this case but he decided to cancel the procedure due to 
the high risk of bleeding. It is possible that a diagnosis of HUS 
may be delayed because anemia and thrombocytopenia can 
also be induced by myelotoxicity secondary to chemotherapy. 
In particular, an elevated reticulocyte count could differenti-
ate between anemia due to myelotoxicity of gemcitabine and 
gemcitabine induced-HUS.19 Furthermore, a sudden decrease in 
hemoglobin, sudden renal failure, uncontrolled hypertension, 
pulmonary congestion, peripheral edema, and thrombocytope-
nia should alert clinicians of the possibility of HUS. When HUS 
is suspected, peripheral blood smears should be screened for the 
presence of fragmented red blood cells and elevated LDH level.20
In conclusion, few cases of gemcitabine-associated HUS have 
been described. With the increase is the use of gemcitabine 
therapy for pancreatic cancer, it is important to quickly and ac-
curately diagnose gemcitabine-associated HUS. This case report 
demonstrates that a patient could overcome this life-threatening 
crisis with early clinical detection and immediate discontinua-
tion of gemcitabine.
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